BAM
IRLA

Bellevue Asset Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Bellevue Asset Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed -$2K – 529
2022
Q1 		$2K Hold
2
– – ﹤0.01% 473
2021
Q4 		$4K Hold
2
– – ﹤0.01% 413
2021
Q3 		$28K Buy
+2
New +$31.8K 0.02% 239

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Bellevue Asset Management's IRLA Position: Q2 2022 in Review

Bellevue Asset Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 2 shares — an estimated $2K sold.

Bellevue Asset Management first reported a position in IRLA in Q3 2021 and held it in 3 quarters. The position peaked at $28K in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

  • Bellevue Asset Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bellevue Asset Management sold 2 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $2K.
  • Bellevue Asset Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Bellevue Asset Management's IRulya Therapeutics Inc. Common Stock position peaked at $28K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Bellevue Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.